Metastatic Prostate Cancer
This recorded webinar will comprise three presentations that provide comprehensive state-of-the-art information on currently available therapies for hormone-naïve prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC).
|Organiser||European School of Urology (ESU)|
|Duration||Approx. 60 minutes|
The therapies will include androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), chemotherapy, radioligand, and poly (ADP-ribose) polymerase (PARP) inhibitors.
The recorded webinar aims to enable participants in optimising treatment combinations and sequences in metastatic prostate cancer at all disease stages.
Prof. B. Tombal (BE)
Dr. C. Thibault (FR)
Prof. Dr. C. Gratzke (DE)
The recording of this webinar is not EU-ACME accredited.
Missed the live session? Earn 1 CME point by completing our online e-course at:
Don't miss this opportunity!
Contact our organiser
European School of Urology (ESU)